This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Biotech Stock Roundup: REGN Up on Q4 Results, VRTX, AXSM Gain on Drug Approval
by Zacks Equity Research
REGN and AMGN are in the spotlight this week on fourth-quarter earnings release.
Company News for Feb 5, 2025
by Zacks Equity Research
Companies In The News Are: RACE, REGN, MPLX, WEC.
Regeneron Beats on Q4 Earnings, Initiates Quarterly Dividend
by Zacks Equity Research
REGN reports better-than-expected Q4 results. However, lead drug Eylea sales decline in the United States due to competition. The company initiates a dividend program,
Compared to Estimates, Regeneron (REGN) Q4 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Regeneron (REGN) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Regeneron (REGN) Q4 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Regeneron (REGN) delivered earnings and revenue surprises of 3.87% and 0.07%, respectively, for the quarter ended December 2024. Do the numbers hold clues to what lies ahead for the stock?
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Regeneron to Report Q4 Earnings: Is a Beat in the Cards?
by Zacks Equity Research
Investors' focus is likely to be on the performance of Dupixent and the uptake of Eylea HD when REGN reports fourth-quarter 2024 results soon.
Ahead of Regeneron (REGN) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Evaluate the expected performance of Regeneron (REGN) for the quarter ended December 2024, looking beyond the conventional Wall Street top-and-bottom-line estimates and examining some of its key metrics for better insight.
Roche's 2024 Sales and Earnings Beat, Key Drugs Perform Well
by Zacks Equity Research
RHHBY records impressive sales growth in 2024 on the back of strong demand for Vabysmo, Hemlibra, Phesgo and Ocrevus.
How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
by Zacks Equity Research
Investors looking for ways to find stocks that are set to beat quarterly earnings estimates should check out the Zacks Earnings ESP.
Sanofi Misses on Q4 Earnings & Sales, Expects Higher Profits in 2025
by Zacks Equity Research
SNY misses Q4 earnings and sales estimates. It expects earnings growth to rebound in 2025. It plans to buy back shares worth 5 billion euro in 2025.
Earnings Preview: GSK (GSK) Q4 Earnings Expected to Decline
by Zacks Equity Research
Glaxo (GSK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
EMA Accepts GSK's Filing for Depemokimab in Two Respiratory Diseases
by Zacks Equity Research
If approved, GSK's depemokimab will be the first ultra-long-acting biologic that requires only one dose every six months.
Earnings Preview: Regeneron (REGN) Q4 Earnings Expected to Decline
by Zacks Equity Research
Regeneron (REGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Implied Volatility Surging for Regeneron Pharmaceuticals (REGN) Stock Options
by Zacks Equity Research
Investors need to pay close attention to Regeneron Pharmaceuticals (REGN) stock based on the movements in the options market lately.
NTLA Begins Dosing in Pivotal Study on Hereditary Angioedema Candidate
by Zacks Equity Research
Intellia doses the first patient in the phase III HAELO study on NTLA-2002 for treating hereditary angioedema. Stock rises.
Intellia Loses 21.6% in a Week: How Should You Play the Stock?
by Ekta Bagri
NTLA stock falls more than 21% in a week after the company announced strategic priorities and key anticipated milestones for 2025. We advise prospective investors to stay on the sidelines for now.
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
by Zacks Equity Research
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
The Zacks Analyst Blog Moderna, Regeneron, Intellia Sage and GSK
by Zacks Equity Research
Moderna, Regeneron, Intellia Sage and GSK are included in this Analyst Blog.
Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates
by Zacks Equity Research
MRNA and NTLA are down this week after providing financial and strategic updates.
Regeneron Reports Eylea Sales, Provides Other Pipeline Updates
by Zacks Equity Research
REGN announces business updates at the J.P. Morgan Healthcare Conference. The company also reports sales for Eylea and Eylea HD (on a preliminary basis).
ALNY Announces Preliminary 2024 Results, 2025 View & Pipeline Goals
by Zacks Equity Research
Alnylam reports preliminary fourth-quarter and full-year 2024 product revenues. The company expects to deliver adjusted operating income profitability in 2025.
Regeneron Stock Plunges 35.6% in Six Months: Fold or Hold?
by Ekta Bagri
REGN's Eylea faces a rapid decline in sales, impacting overall performance even though Dupixent maintains momentum. We advise investors to stay on the sidelines for now.
Why Regeneron (REGN) is Poised to Beat Earnings Estimates Again
by Zacks Equity Research
Regeneron (REGN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.